Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Roivant Sciences (ROIV) EPS (Weighted Average and Diluted) (2021 - 2025)

Roivant Sciences (ROIV) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with -$0.39 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) fell 269.57% year-over-year to -$0.39, compared with a TTM value of -$0.65 through Dec 2025, down 110.91%, and an annual FY2025 reading of -$0.75, down 114.34% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.39 for Q4 2025 at Roivant Sciences, down from -$0.16 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $6.03 in Q4 2023 and bottomed at -$0.87 in Q4 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is $0.11, with a median of -$0.33 recorded in 2025.
  • The sharpest move saw EPS (Weighted Average and Diluted) skyrocketed 1330.61% in 2023, then crashed 3400.0% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.87 in 2021, then skyrocketed by 43.68% to -$0.49 in 2022, then skyrocketed by 1330.61% to $6.03 in 2023, then crashed by 96.19% to $0.23 in 2024, then crashed by 269.57% to -$0.39 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for ROIV at -$0.39 in Q4 2025, -$0.16 in Q3 2025, and -$0.33 in Q2 2025.